Navigation Links
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Date:1/4/2008

of RX-1741 in the treatment of adult patients with mild to moderate severity of Community-Acquired Pneumonia (CAP). The study will assess the efficacy of three doses of RX-1741, either once or twice a day, for seven to 10 days in the treatment of adult patients with mild to moderate CAP. It will also evaluate the safety and tolerability profile of the three doses.

The CAP study will enroll approximately 160 patients in 40 study centers across the US, Canada, and Russia, and the Company expects to have preliminary data available when approximately 80 patients (50% of the planned patients) have completed the study. The Company intends to release data from all patients during the first half of 2008.

uSSSI Study Design

The uSSSI study is a Phase 2, multicenter, randomized, open-label, comparative study to evaluate the safety and efficacy of RX-1741 versus linezolid in the outpatient treatment of adult patients with Uncomplicated Skin and Skin Structure Infections (uSSSI). The study will assess the efficacy of a single dose of RX-1741 given either once daily or twice daily compared to linezolid given twice daily for five to ten days in the treatment of ambulatory patients with uSSSI. It will also evaluate the safety and tolerability profile of these two doses compared to linezolid.

The uSSSI study will enroll approximately 150 patients in 25 study centers across the US and the Company expects an interim analysis of the data to be performed when approximately 75 patients (50% of the planned patients) have completed the study. The Company intends to release data from all patients during the first half of 2008.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the 50S subun
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
2. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
9. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... - Aegera Therapeutics announced today,the initiation of ... AEG33773, a,novel, orally bioavailable small molecule in ... The Phase I study will evaluate the ... a randomized,double blind, placebo controlled, single ascending ...
... that improve the, safety, effectiveness, and environmental impact of ... new denitrification ... products-, ... today that the company has closed the first,tranche of a $2.5 ...
... Litigation with US Labs, FT. MYERS, Fla., March ... its results for the fourth,quarter and full year of ... year included the following:, Fourth Quarter 2007 ... of 115% year-over-year from Q4 06 -- Avg. ...
Cached Biology Technology:Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 3Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 4NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 2NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 3NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 4NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 5NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 6NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 7NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 8NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007 9
(Date:4/16/2014)... Boulder, Colorado, USA - Geoscientists from the north-central U.S. ... 24-25 April to discuss new science, expand on existing ... of the region, with a special emphasis on applied ... talk at 7 p.m. on Thursday by Dr. Kirk ... Natural History. , The meeting is hosted by ...
(Date:4/16/2014)... or to conquer the world? Surprisingly, bacteria also ... in Munich have now shown how these organisms ... , The bacterium Bacillus subtilis is ... on agar surfaces by means of flagella. Alternatively, ... the bacteria proliferate most effectively in this stationary ...
(Date:4/15/2014)... UC Irvine neurobiologists have found that genetically modified neural ... brains of mice with the symptoms and pathology of ... journal Stem Cells Research and Therapy , and ... different mouse models. , Alzheimer,s disease, one of ... accumulation of the protein amyloid-beta in the brain in ...
Breaking Biology News(10 mins):Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4Theoretical biophysics: Adventurous bacteria 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
... University researchers have discovered men with an unusual form ... men the same age who are cognitively normal. , ... disease in which people have trouble recalling and understanding ... themselves and understand speech. It differs from typical Alzheimer's ...
... study in Switzerland uses the tools of physics to ... time in the noisy cellular environment. , In ... Systems Biology, researchers from the Ecole Polytechnique Federale de ... on specific biochemical processes, reflecting recent association studies in ...
... A complex molecule and snake venom may provide researchers ... and developing new drugs. , Purdue University researchers bound ... identification tag that was delivered to specific proteins in ... to find a better way to ascertain the presence, ...
Cached Biology News:Vasectomy may put men at risk for type of dementia 2Vasectomy may put men at risk for type of dementia 3Keeping the body in sync -- The stability of cellular clocks 2Scientists use nanoparticle to discover disease-causing proteins 2
... combines a single-channel sample processing head, an ... reagent dispenser all in one compact, affordable ... pipette tips, the Precision XS autoclavable and ... available for transferring larger volumes. Intuitive Precision ...
... races ever faster, you need a partner who ... our constant focus is on providing tools and ... our Biomek 3000 Laboratory Automation Workstation offers a ... is flexible. By integrating all aspects of liquid ...
... Rabbit Tissue Arrays contain 60 rabbit tissue samples ... contains 4 unstained slides and 1 hematoxylin and ... slide contains 15 different tissues from 4 rabbit ... per slide. Each tissue sample (or core) is ...
... with a wide variety of purity levels, scales ... Purity: IG(>50%), >70%, >80% and ... Sequence Length: Up to 120 residues ... D-amino acids, MAPs, KLH/BSA conjugation, and much more. ...
Biology Products: